An open dataset about georeferenced harmonized national agricultural censuses and surveys of seven mediterranean countries

[EN] The dataset presented in this paper is based on data gathered from several countries within the West Mediterranean area at the highest detailed scale regarding official statistics, with the aim of investigating land and food systems dynamics in the Mediterranean. Characterizing land and food systems dynamics is critical to reveal insights regarding interactions between current dynamics of agricultural practices, species diversity and local food systems. These interactions were analyzed, at multiple spatial scales, on a large part of the Mediterranean basin within the DIVERCROP Project (https://divercropblog.wordpress.com/). An harmonized dataset with the desired characteristics was not readily available from official sources and, therefore, it was necessary to build an ad hoc database that could: (1) cover the Mediterranean areas of seven countries, namely Algeria (DZ), France (FR), Italy (IT), Malta (MT), Portugal (PT), Spain (ES) and Tunisia (TN); (2) contain data referred to the most disaggregated level of administrative units for which data is available in each country; (3) contain data referred to at least two time points, including the latest available data, in each country; (4) contain data on number of farm holdings, on the physical areas covered by the main annual and permanent crops and on livestock (number of heads); (5) contain a primary key that allows joining the census and surveys database to a geographical dataset of administrative units covering the entire area; (6) have an associated complete geographical dataset of administrative units, to allow spatial data analyses.DIVERCROP is funded through the ARIMNet2 2016 Call by the following funding agencies: ANR, IRESA (Tunisia), INIA (Spain), FCT (Portugal), ATRSNV (Algeria), MiPAAF (Italy) and MCST. ARIMNet2 (ERA-NET) has received funding from the European Union s Seventh Framework Programme for research, technological development and demonstration under grant agreement n 618127. Special thanks to all of the local partners of the DIVERCROP project for collaborating on data collection, discussing the method and validating the results.Villani, R.; Sabbatini, T.; Moreno-Pérez, OM.; Guiomar, N.; Debolini, M. (2019). An open dataset about georeferenced harmonized national agricultural censuses and surveys of seven mediterranean countries. Data in Brief. 27:1-8. https://doi.org/10.1016/j.dib.2019.104774S182

Distributional and classical solutions to the Cauchy Boltzmann problem for soft potentials with integrable angular cross section

This paper focuses on the study of existence and uniqueness of distributional and classical solutions to the Cauchy Boltzmann problem for the soft potential case assuming $S^{n-1}$ integrability of the angular part of the collision kernel (Grad cut-off assumption). For this purpose we revisit the Kaniel--Shinbrot iteration technique to present an elementary proof of existence and uniqueness results that includes large data near a local Maxwellian regime with possibly infinite initial mass. We study the propagation of regularity using a recent estimate for the positive collision operator given in [3], by E. Carneiro and the authors, that permits to study such propagation without additional conditions on the collision kernel. Finally, an $L^{p}$-stability result (with $1\leq p\leq\infty$) is presented assuming the aforementioned condition.Comment: 19 page

LIFE+IPNOA mobile prototype for the monitoring of soil N2O emissions from arable crops: First-year results on durum wheat

Agricultural activities are co-responsible for the emission of the most important greenhouse gases: carbon dioxide (CO2), methane (CH4) and nitrous oxide (N2O). Development of methodologies to improve monitoring techniques for N2O are still needful. The LIFE+IPNOA project aims to improve the emissions monitoring of nitrous oxide from agricultural soils and to identify the agricultural practices that can limit N2O production. In order to achieve this objective, both a mobile and a stationary instrument were developed and validated. Several experimental field trials were set up in two different sites investigating the most representative crops of Tuscany (CentralItaly), namely durum wheat, maize, sunflower, tomato and faba bean. The field trials were realized in order to test the effect on N2O emissions of key factors: tillage intensity, nitrogen fertiliser rate and irrigation. The field trial on durum wheat was set up in 2013 to test the effect of tillage intensity (minimum and conventional tillage) and nitrogen fertilisation rate (0, 110, 170 kg N ha–1) on soil N2O flux. Monitoring was carried out using the IPNOA mobile prototype. Preliminary results on N2O emissions for the durum wheat growing season showed that mean daily N2O fluxes ranged from –0.13 to 6.43 mg m–2 day–1 and cumulative N2O-N emissions over the period ranged from 827 to 2340 g N2O-N ha–1. Tillage did not affect N2O flux while increasing nitrogen fertilisation rate resulted to significantly increase N2O emissions. The IPNOA mobile prototype performed well during this first year of monitoring, allowing to catch both very low fluxes and peaks on N2O emissions after nitrogen supply, showing a good suitability to the field conditions

Is it really advantageous to operate proximal femoral fractures within 48 h from diagnosis? – A multicentric retrospective study exploiting COVID pandemic-related delays in time to surgery

Objectives: Hip fractures in the elderly are common injuries that need timely surgical management. Since the beginning of the pandemic, patients with a proximal femoral fracture (PFF) experienced a delay in time to surgery. The primary aim of this study was to evaluate a possible variation in mortality in patients with PFF when comparing COVID-19 negative versus positive. Methods: This is a multicentric and retrospective study including 3232 patients with PFF who underwent surgical management. The variables taken into account were age, gender, the time elapsed between arrival at the emergency room and intervention, pre-operative American Society of Anesthesiology score, pre-operative cardiovascular and respiratory disease, and 10-day/1-month/6-month mortality. For 2020, we had an additional column, “COVID-19 swab positivity.” Results: COVID-19 infection represents an independent mortality risk factor in patients with PFFs. Despite the delay in time-to-surgery occurring in 2020, no statistically significant variation in terms of mortality was detected. Within our sample, a statistically significant difference was not detected in terms of mortality at 6 months, in patients operated within and beyond 48 h, as well as no difference between those operated within or after 12/24/72 h. The mortality rate among subjects with PFF who tested positive for COVID-19 was statistically significantly higher than in patients with PFF who tested. COVID-19 positivity resulted in an independent factor for mortality after PFF. Conclusion: Despite the most recent literature recommending operating PFF patients as soon as possible, no significant difference in mortality was found among patients operated before or after 48 h from diagnosis

Analysis of shared common genetic risk between amyotrophic lateral sclerosis and epilepsy

Because hyper-excitability has been shown to be a shared pathophysiological mechanism, we used the latest and largest genome-wide studies in amyotrophic lateral sclerosis (n = 36,052) and epilepsy (n = 38,349) to determine genetic overlap between these conditions. First, we showed no significant genetic correlation, also when binned on minor allele frequency. Second, we confirmed the absence of polygenic overlap using genomic risk score analysis. Finally, we did not identify pleiotropic variants in meta-analyses of the 2 diseases. Our findings indicate that amyotrophic lateral sclerosis and epilepsy do not share common genetic risk, showing that hyper-excitability in both disorders has distinct origins

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed